Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

News | Cardiovascular Ultrasound | November 14, 2019
November 14, 2019 — Ultromics has received 510(k) clearance from the U.S.
Global Echocardiography Normal Values Study Presented at European Society of Cardiology Congress
News | Cardiovascular Ultrasound | September 04, 2019
September 4, 2019 — Final data from the World Alliance Societies of Echocardiography (WASE) Normal Values...
Terason Partners With DiA Imaging Analysis for Point-of-care Cardiac Ultrasound AI
News | Cardiovascular Ultrasound | August 26, 2019
Ultrasound imaging company Terason has partnered with DiA Imaging Analysis, provider of artificial intelligence (AI)-...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
360 Photos | Cardiovascular Ultrasound | July 11, 2019
This is a 360 degree view of a live cardiac echo demonstration for the Siemens Healthineers Acuson SC2000 ...
ASE 2019 virtual reality demonstration with TomTec which showed hot VR can be used to review complex 3-D anatomy and make more accurate measurements on cardiac imaging.

A virtual reality demonstration by TomTec, showing how VR can be used to review complex 3-D anatomy and make more accurate measurements on cardiac imaging.

Feature | Cardiovascular Ultrasound | July 10, 2019 | Dave Fornell, Editor
Here is an overview of the hot topics and new technology trends in cardiovascular ultrasound from the 2019 American S
Videos | Cardiovascular Ultrasound | July 10, 2019
This is an example of a cardiac echocardiography exam performed using an iPhone and the Butterfly IQ ultrasound trans
360 Photos | Cardiovascular Ultrasound | July 10, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
360 Photos | Cardiovascular Ultrasound | July 10, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
360 Photos | Cardiovascular Ultrasound | July 09, 2019
A view of a mitral valve on a GE Healthcare Vivid E95...
Overlay Init